This study is currently not recruiting participants.

A Phase 1 Dose-Escalation Study to Determine the Safety of TH-302 in Combination with Sunitinib in Patients with Advanced Renal Cell Carcinoma Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors

Study of Safe Dosing Levels for Investigational Medications

Not Recruiting
18 years - 100 years
All
Phase N/A

Brief description of study.

The main purpose of the study is to find out the highest and safest levels of two drugs when they are given together.

Detailed description of study

The main purpose of the study is to find out the highest and safest levels of two drugs when they are given together.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Kidney,Pancreatic Cancers
  • Age: 18 years - 100 years
  • Gender: All

This study investigates the safe and effective dosing levels of two investigational medications when administered together. The goal is to determine the highest dose that can be given safely without causing harmful side effects.

Participants will receive different doses of the investigational medications to assess safety and tolerability. The study will monitor participants closely to ensure their safety and to collect necessary data on how the medications interact.

  • Who can participate: The study is open to individuals who meet specific health criteria. Participants must be adults aged 18 and over who are in good general health.
  • Study details: Participants will receive doses of the investigational medications and be observed for any side effects. A placebo, an inactive substance that looks like the investigational medication but does not contain any medicine, may be used for comparison.
Updated on 19 Feb 2024. Study ID: 1208009271

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team